当前位置:首页 / 科学研究 / 实验室 / 正文

实验室

15:00-16:00, Friday, August 30, 2019


Speaker: Chengcheng (Alec) Zhang, Ph.D.

Professor,

UT Southwestern Medical Center

Topic: Targeting ITIM-receptors for cancer treatment

Host:  Xiaodong Wang, Ph.D.

Abstract

Inhibitory leukocyte immunoglobulin-like receptors (LILRBs 1-5) transduce signals via intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit protein tyrosine phosphatase non-receptor type 6 (PTPN6 or SHP-1), protein tyrosine phosphatase non-receptor type 11 (PTPN11 or SHP-2), or Src homology 2 domain-containing inositol phosphatase (SHIP), leading to negative regulation of immune cell activation. The activation of LILRBs on immune cells, especially immunosuppressive myeloid cells, by their ligands may contribute to immune evasion by tumors. Recent studies also found that several members of LILRB family are expressed by tumor cells, notably hematopoietic cancer cells, and may directly regulate cancer development and relapse. LILRBs thus have dual concordant roles in tumor biology – as immune checkpoint molecules and as tumor-sustaining factors. Importantly, the study of knockout mice indicated that LILRBs do not affect hematopoiesis and normal development. Therefore LILRBs may represent ideal targets for tumor treatment that combines targeted therapy and immunotherapy. I will discuss our recent work about the roles of LILRBs in development of leukemia and solid cancers.